What Happens During a Transfusion Reaction?

Transfusion reactions are unwanted responses that occur during or after a blood transfusion, ranging from mild fevers and hives to rare, life-threatening emergencies. The vast majority are mild. U.S. hemovigilance data from over eight million transfusions found roughly 220 adverse reactions per 100,000 components transfused, with allergic reactions making up about 41% and only 9% classified as serious.

How Common They Are and What Most Look Like

If you receive a blood transfusion, the odds of having any reaction are low but not negligible. A large surveillance study spanning 2013 to 2018 through the U.S. National Healthcare Safety Network logged 18,308 reactions among 8.34 million transfused components. Most were allergic (hives, itching, mild swelling) or febrile, meaning the patient spiked a fever without anything more dangerous going on. Only 23 of those reactions were fatal.¹ A separate four-year study at a single center in India found reactions in about 0.5% of all transfusions, with febrile non-hemolytic reactions accounting for just over half and allergic reactions making up 40%.² A cross-country comparison looking at red blood cell transfusions across 17 nations confirmed that febrile non-hemolytic reactions and delayed serologic reactions were the most commonly reported events, each occurring in roughly 25 to 26 patients per 100,000 units transfused.³

Rates vary by product type. Platelet transfusions carry a higher reaction rate than red blood cells, in part because platelets are stored at room temperature and accumulate inflammatory signaling molecules over their shelf life. In the U.S. data, pathogen-reduced platelets had a reported adverse reaction rate of 579 per 100,000, compared with 197 per 100,000 for red blood cells collected by apheresis.⁴

Febrile Reactions and Why They Happen

The single most common transfusion reaction is a fever with chills that shows up during or shortly after a transfusion, without any sign of the red blood cells actually being destroyed. These febrile non-hemolytic reactions are uncomfortable but not dangerous in themselves. The underlying cause, at least for platelet transfusions, is largely cytokines: inflammatory molecules released by white blood cells and platelets that build up in the stored product over time. Research has shown that removing the liquid portion of stored platelets before transfusion significantly lowers the frequency and severity of these fevers.⁵

One of the most effective strategies against febrile reactions is leukoreduction, which means filtering out white blood cells before or shortly after the blood is collected. When filtering happens before storage (prestorage leukoreduction), fewer cytokines accumulate in the product during its shelf life. Studies have confirmed that prestorage leukoreduction significantly cuts the rate of febrile reactions in red blood cell transfusions and allergic reactions in platelet transfusions, likely because it prevents the inflammatory molecules from building up in the first place.⁶ In many countries, universal prestorage leukoreduction is now standard practice.

Allergic and Anaphylactic Reactions

Allergic reactions to transfusions usually present as hives, itching, or localized swelling and are treated by slowing or temporarily stopping the transfusion and giving antihistamines. These are common and almost always resolve without lasting harm. Anaphylaxis during transfusion is a different story: it’s rare but can involve throat swelling, a dangerous drop in blood pressure, and difficulty breathing. It requires immediate treatment with epinephrine and other emergency measures.

A well-known cause of severe anaphylactic transfusion reactions is an antibody directed against immunoglobulin A (IgA). People who are IgA-deficient can develop antibodies against IgA, and when they receive a blood product containing IgA, a severe allergic response can follow. However, the actual proportion of suspected anaphylactic transfusion reactions caused by anti-IgA is smaller than many assume. In a study testing sera from patients referred for suspected IgA-related anaphylaxis, an IgA antibody was confirmed in about three-quarters of IgA-deficient patients, but only about 18% of all referred samples contained an IgA antibody. The majority of suspected cases turned out to have other causes entirely.⁷ So while IgA deficiency gets much of the blame for anaphylactic transfusion reactions in textbooks, most of these events actually stem from something else.

Hemolytic Reactions and Blood Type Mismatches

The most feared acute transfusion reaction is an acute hemolytic reaction, where the recipient’s immune system attacks and destroys the transfused red blood cells. The classic scenario is an ABO mismatch: say a patient with type O blood receives type B red blood cells. The patient’s natural anti-B antibodies latch onto the foreign cells and trigger a cascade of complement activation. That cascade does two things simultaneously: it ruptures the transfused red blood cells (hemolysis), releasing their contents into the bloodstream, and it sets off a widespread inflammatory response. The released hemoglobin and the inflammatory signaling can cause fever, a sharp drop in blood pressure, kidney damage, and dangerous clotting abnormalities.⁸

ABO-incompatible transfusions are overwhelmingly the result of human error: mislabeled samples, wrong patient, wrong unit pulled from the refrigerator. The reaction itself is a medical emergency, but the root cause is almost always a system failure, not a biological mystery. This is why so much of transfusion safety engineering focuses on identification and verification at the bedside.

Delayed Hemolytic Reactions

Not all hemolytic reactions happen right away. Delayed hemolytic transfusion reactions show up anywhere from three to ten days after a transfusion and involve a different mechanism. These occur in patients who were previously sensitized to minor red blood cell antigens, typically through an earlier transfusion or pregnancy, but whose antibody levels have dropped low enough that standard pretransfusion testing doesn’t detect them. When the patient receives blood carrying that antigen again, the immune system ramps up antibody production quickly, and the transfused cells are destroyed over the following days.⁹ Patients may notice a falling blood count, mild jaundice, or dark urine. These reactions can range from barely noticeable to clinically significant, particularly in patients with conditions like sickle cell disease who rely on regular transfusions.

Lung-Related Complications

Two transfusion complications center on the lungs: transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO). Both cause breathing difficulty and fluid in the lungs, but they arise from fundamentally different problems, and telling them apart matters because the treatments differ.

TRALI is an immune-mediated condition. The current understanding is a “two-hit” model: the patient typically has some underlying predisposition (an infection, recent surgery, or other inflammatory state), and antibodies or other biologically active substances in the donated blood deliver the second hit that triggers damage to the lung’s tiny blood vessels. Research using laboratory models of lung injury has confirmed that damage to lung endothelial cells requires both an underlying inflammatory priming event and the antibody-driven insult; neither alone is sufficient.¹⁰ TRALI incidence has dropped in recent years, largely because blood banks now use male-predominant plasma donors (female donors who have been pregnant are more likely to carry the antibodies that trigger it).

TACO, by contrast, is a volume problem. If blood is transfused too fast or in too large a quantity for a patient whose heart or kidneys cannot handle the extra fluid, the lungs fill up. Patients at highest risk include older adults, those with heart failure, and small children. Distinguishing TACO from TRALI clinically can be tricky, though lab tests help. A systematic review found that a specific blood marker (the ratio of post-transfusion to pre-transfusion NT-proBNP above 1.5) aids in TACO diagnosis, while a post-transfusion level below 2,000 pg/mL makes TACO unlikely.¹¹ That said, in critically ill patients these biomarkers become much less specific, and no cytokine profile can cleanly separate TACO from TRALI in every case.

Metabolic Fallout in Massive Transfusion

When patients receive many units of blood in a short time, as in major trauma or surgical hemorrhage, a cluster of metabolic problems can compound each other. Stored blood differs from what’s circulating in your veins in several important ways, and those differences become dangerous at volume.

One key issue is citrate, the anticoagulant used to keep stored blood from clotting. Normally your liver clears citrate quickly, but during massive transfusion the citrate load overwhelms the liver’s capacity. Citrate binds calcium in the bloodstream, driving down ionized calcium levels. Low calcium impairs both heart function and blood clotting. This creates a vicious cycle sometimes called the “diamond of death”: bleeding leads to more transfusion, which delivers more citrate, which worsens clotting, which leads to more bleeding.¹² Hypothermia and acidosis, both common in massive bleeding, further slow citrate clearance and make the spiral worse. Trauma teams now give supplemental calcium during massive transfusion protocols, though the optimal dose remains an active area of study.¹³

Potassium is the other metabolic landmine. Red blood cells slowly leak potassium into the surrounding fluid during storage, and the concentration rises roughly in proportion to how old the unit is.¹⁴ A single unit rarely causes trouble, but when multiple older units are transfused rapidly, the potassium load can cause dangerous heart rhythm abnormalities. Cold blood adds another risk: massive transfusion of refrigerated blood can drop body temperature to levels that impair the heart’s electrical conduction. Esophageal temperatures as low as 27.5°C have been recorded at the time of cardiac arrest in patients receiving large volumes of cold stored blood.¹⁵ Modern blood warmers are designed to prevent this, but the risk underscores why massive transfusion is managed with dedicated protocols rather than simply ordering more units.

Infectious Risks Today

Transfusion-transmitted infections dominated public concern in the 1980s and 1990s, and for good reason: contaminated blood spread HIV and hepatitis C to thousands of people. Modern screening has transformed this risk. Testing donated blood for viral genetic material (nucleic acid testing, or NAT) catches infections in donors who haven’t yet developed detectable antibodies. In Italy, seven years of NAT data estimated the residual risk of an HIV-positive unit entering the blood supply at roughly one in 1.9 million donations, and for hepatitis C about one in 13 million.¹⁶ In South Africa, an individual-donation NAT program identified just one hepatitis B transmission among roughly 2.9 million donations tested, and even that case involved an extremely low viral load in a window-period donor.¹⁷

Bacterial contamination is a more pressing everyday concern than viruses, particularly for platelets. Because platelets must be stored at room temperature to stay functional, bacteria introduced during collection (mostly from the donor’s skin) can multiply during storage. Enteric bacteria are rarer contaminants but can be devastating if they make it in.¹⁸ Newer pathogen-reduction technologies use ultraviolet light to damage the DNA of contaminating organisms. One UVC-based system tested against a panel of bacteria relevant to transfusion achieved large reductions in bacterial counts, and platelet units spiked with low levels of bacteria remained sterile through the end of storage when treated within six hours.¹⁹

Rare But Dangerous Complications

A few transfusion reactions are exceptionally uncommon but disproportionately severe.

Transfusion-associated graft-versus-host disease (TA-GVHD) occurs when viable donor immune cells in the transfused product attack the recipient’s tissues. Unlike the graft-versus-host disease seen after bone marrow transplants, the transfusion-associated form is almost uniformly fatal because the recipient’s own bone marrow is also targeted. Leukoreduction decreases the number of donor white blood cells but cannot fully prevent TA-GVHD, because even small numbers of surviving donor T cells can proliferate in a susceptible host. Irradiating blood products with gamma rays or X-rays before transfusion remains the most reliable prevention, as it damages donor T-cell DNA enough to stop them from dividing.²⁰ Irradiation is standard for transfusions to immunocompromised patients and for directed donations from blood relatives, where shared genetic markers make TA-GVHD more likely.

Post-transfusion purpura (PTP) is another rare reaction in which a patient’s platelet count plummets about a week after transfusion, causing bruising and sometimes dangerous bleeding. It is driven by antibodies against platelet-specific antigens, most commonly HPA-1a, that paradoxically destroy the patient’s own platelets along with the transfused ones.²¹ PTP is seen predominantly in women who were sensitized during pregnancy and is treated with intravenous immunoglobulin. It is easily missed because the drop in platelet count occurs days after the transfusion and might be attributed to other causes in a hospitalized patient. Rarer antibody targets like HPA-5b have also been identified.²²

Iron Overload From Chronic Transfusion

For patients who depend on regular red blood cell transfusions over months or years, like those with thalassemia, sickle cell disease, or certain bone marrow failure syndromes, the body accumulates iron that it has no efficient way to excrete.²³ Each unit of red blood cells contains roughly 200 to 250 milligrams of iron, and after enough transfusions the excess iron deposits in the heart, liver, pancreas, and endocrine glands, causing organ damage over time.²⁴ Iron chelation therapy, drugs that bind excess iron so it can be excreted, is the standard approach to prevent or slow this damage. Monitoring typically involves periodic blood tests for ferritin levels and sometimes MRI scans of the heart and liver to estimate iron concentration. The challenge for patients is that chelation therapy must be maintained consistently alongside their transfusion schedule, which can be a significant burden.

Preventing Reactions Before They Start

The most effective prevention strategies target the two biggest failure points: giving blood to the wrong patient and giving more blood than necessary.

Mistransfusion, delivering the wrong blood component to the wrong patient, is the leading cause of the most dangerous acute hemolytic reactions. Technology has made a measurable difference. A study of nearly 16,000 transfusions in operating rooms found that a barcode scanning system designed for the surgical environment detected 45 potential transfusion errors and prevented 36 mismatched products from being given to 20 patients. When providers used the scanner, no transfusion errors or reactions were reported.²⁵ Barcoded wristbands and blood tubes create a chain of verification from the lab to the bedside, and nurses in some studies preferred the scanning approach over the traditional method of having a second nurse manually verify the match.²⁶

The other major prevention lever is simply transfusing less. Over the past two decades, clinical practice has shifted toward restrictive transfusion thresholds, meaning transfusion is not considered until hemoglobin drops to a lower level than was once standard. The AABB clinical practice guidelines, based on dozens of randomized trials, established that waiting to transfuse until hemoglobin falls to 7-8 g/dL (rather than the older 9-10 g/dL threshold) was not associated with higher rates of death, heart attacks, stroke, or infection.²⁷ A Cochrane review covering 48 trials and more than 20,000 participants confirmed this finding and showed that restrictive thresholds reduced the chance of receiving a transfusion at all by about 42%, with no increase in 30-day mortality or other serious outcomes.²⁸ Fewer transfusions means fewer opportunities for any reaction to occur.

How Reactions Are Tracked at a National Level

Hemovigilance, the systematic surveillance of adverse events related to blood transfusion, is how health systems spot trends and improve safety over time. In the United States, the National Healthcare Safety Network’s Hemovigilance Module collects data on the frequency, severity, and likelihood of causation for transfusion-related adverse events.²⁹ Participation is voluntary, which means the data tend to come from larger academic centers and may undercount events at smaller facilities. Germany’s national hemovigilance system takes a different approach, requiring standardized reporting criteria for reaction types and severity, which allows for consistent monitoring across the country over time.³⁰ These systems are the reason we know TRALI incidence has dropped after policy changes in donor selection, or that allergic reactions are the most commonly reported events in the U.S. Without them, changes in practice would be based on anecdote rather than data.

Transfusion Reactions in Children

Children are not just small adults when it comes to transfusion safety, and the pattern of reactions in pediatric patients differs from what is seen in adults in ways that surprise even some clinicians. Overall, the incidence of transfusion reactions is higher in children than in adults.³¹ But the age breakdown tells a more nuanced story. A study in New Zealand found that neonates and infants, who accounted for three-quarters of pediatric transfusion recipients, actually had lower reaction rates than adults. The elevated risk was concentrated in children older than two years, driven mainly by allergic reactions. Number of transfusions and receiving multiple types of blood components were the strongest risk factors for reactions in this age group.³²

Febrile, allergic, and hypotensive reactions, along with volume overload, are the most common types in children. Volume overload deserves particular attention in very small patients, where even modest fluid volumes relative to body weight can be clinically meaningful. Platelet transfusions were most commonly associated with reactions in pediatric recipients, followed by plasma and then red blood cells, a ranking that mirrors the adult pattern but with higher overall rates.³³ An interesting demographic detail: prior to age 11, boys made up the majority of pediatric transfusion recipients, likely reflecting the higher rate of trauma and certain cancers in young males. After age 13, the gender balance flipped, and girls became more likely both to receive transfusions and to experience adverse reactions.³⁴

What Happens at the Bedside When a Reaction Is Suspected

When a patient develops new symptoms during a transfusion, the universal first step is stopping the transfusion and keeping the IV line open with normal saline. This buys time while clinicians figure out whether they’re dealing with something mild or something catastrophic. Vital signs are reassessed, and the blood product and tubing are typically sent back to the blood bank for investigation. A clerical check is done immediately to confirm the right unit went to the right patient, because if an ABO mismatch is the cause, time matters.

Further workup depends on severity. For a simple allergic reaction, antihistamines and observation may be enough, and the transfusion can sometimes be restarted slowly. For a suspected hemolytic reaction, blood and urine samples are drawn to look for signs of red cell destruction: free hemoglobin in the blood, hemoglobin in the urine, a falling blood count, rising bilirubin. A direct antiglobulin test (Coombs test) checks whether antibodies have coated the transfused red cells. For suspected TRALI, a chest X-ray typically shows bilateral lung infiltrates without signs of heart failure, and the blood bank may test for antibodies in the donor’s plasma. For reactions that involve fever alone, the key question is whether it’s truly benign or whether it’s the first sign of bacterial contamination or hemolysis. Blood cultures from both the patient and the blood product help answer that question.

The investigative burden can feel disproportionate to the symptom, especially for a patient who just has a mild fever. But the overlap in early symptoms between benign febrile reactions and life-threatening hemolysis or sepsis is real, and the cost of missing a dangerous diagnosis is high. That tension drives the deliberately cautious bedside protocols that govern every transfusion reaction workup.